Clinical Trial Update: A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of Ad-RTS-hIL-12 plus Veledimex in pediatric brain tumors including diffuse intrinsic pontine glioma was terminated, and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-12